Key Highlights
- Amylyx Pharmaceuticals shares are up 16% at $24.80 during extended hours.
- The company is scheduled to disclose primary Phase 3 LUCIDITY data on August 18, 2026.
- The trial evaluates avexitide for post-bariatric hypoglycemia.
- Leadership will conduct a conference call and webcast at 8:00 AM ET to review the clinical findings.
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) shares are up 16% at $24.80 during extended hours ahead of the company's scheduled disclosure of primary data from its Phase 3 LUCIDITY study evaluating avexitide for post-bariatric hypoglycemia on August 18, 2026.
What Happened
Following the announcement, Leadership will conduct a conference call and webcast at 8:00 AM ET to review the clinical findings.
Market Reaction
Shares rose in extended trading as investors positioned ahead of the scheduled data disclosure, reflecting anticipation heading into the readout for avexitide in post-bariatric hypoglycemia.
Outlook
The scheduled August 18, 2026 data disclosure and accompanying conference call represent the immediate next catalyst for Amylyx Pharmaceuticals' stock, with the actual trial results likely to be the primary driver of the stock's direction following the announcement.
FAQs
Q: Why did Amylyx Pharmaceuticals shares rise 16% in extended hours?
A: Shares rose as investors positioned ahead of the company's scheduled disclosure of primary Phase 3 LUCIDITY data on August 18, 2026.
Q: What is the LUCIDITY trial evaluating?
A: Avexitide for the treatment of post-bariatric hypoglycemia.
Q: When is the conference call to review the data?
A: 8:00 AM ET on August 18, 2026, following the data disclosure.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.